To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Jun 3, 2026 - P3 | N=510 | Not yet recruiting | Sponsor: Daewoong Pharmaceutical Co. LTD.
Monotherapy • New P3 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
|